查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1908649

GLP-1受體促效劑市場規模、佔有率和趨勢分析報告：按產品、應用、給藥途徑、分銷管道、地區和細分市場預測（2026-2033年）

GLP-1 Receptor Agonist Market Size, Share & Trends Analysis Report By Product (Trulicity, Wegovy, Ozempic, Mounjaro), By Application (Diabetes, Obesity), By Route Of Administration, By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

GLP-1受體促效劑市場概況

全球 GLP-1 受體促效劑市場預計在 2025 年達到 700.8 億美元，預計到 2033 年將達到 2,017.9 億美元。

預計從 2026 年到 2033 年，該市場將以 12.78% 的複合年成長率成長。新型類升糖素肽-1 (GLP-1) 受體促效劑產品的推出、糖尿病和肥胖症治療領域強大的產品平臺以及這些藥物的高療效，預計將推動市場成長。

2024年5月，信達生物宣布，其候選第2型糖尿病治療藥物馬度胜肽在3期臨床試驗中療效優於禮來公司的度拉糖肽（Dulaglutide）。該試驗證實，馬度胜肽在血糖控制方面表現較佳，並帶來許多心血管代謝的益處，包括改善減重、血脂水平、肝臟酵素、血清尿酸和血壓。

包括勃林格殷格翰國際有限公司、Carmot Therapeutics公司、D&D Pharmatech公司、禮來公司（禮來）和韓美製藥股份有限公司在內的其他公司也在致力於開發新型類升糖素肽-1（GLP-1）藥物。例如，2023年10月，Carmot Therapeutics公司公佈了其正在進行的口服小分子GLP-1受體促效劑（RA）CT-996的I期臨床試驗單次遞增劑量（SAD）階段的初步結果。該藥物目前正在超重或肥胖受試者中進行首次人體臨床試驗。因此，GLP-1受體促效劑領域的研究不斷增加預計將推動市場成長。

此外，肥胖和糖尿病盛行率的不斷上升預計將推動GLP-1受體促效劑產業的成長。超重和肥胖者罹患糖尿病和心血管疾病的風險更高。全球肥胖率持續上升，已被廣泛認為是當今主要的公共衛生問題之一。根據世界心臟聯盟估計，全球約有23億兒童和成人患有肥胖或超重。此外，根據肥胖行動聯盟（OAC）的數據，超過90%的第二型糖尿病患者超重或有不同程度的肥胖。因此，不斷成長的肥胖和糖尿病患者群體正在推動全球對治療性GLP-1受體促效劑的需求。

市場成長的促進因素包括：與其它藥物相比，GLP-1 類藥物具有顯著優勢；以及對新型 GLP-1 類藥物研發投入的不斷增加。一些 GLP促效劑與體重減輕或體重維持在正常範圍內相關，這對糖尿病患者尤其有益，因為肥胖通常會加重糖尿病病情。抑制食慾和延緩排放是其發揮減重作用的關鍵機制。此外，諾和諾德公司於 2023 年 11 月宣布計畫投資約 160 億丹麥克朗（約 23.2 億美元/21.4 億歐元）用於 GLP-1 類藥物的研發。這些舉措預計將進一步推動市場成長。

目錄

第1章調查方法和範圍

第2章執行摘要

3. GLP-1受體促效劑市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
  • GLP-1受體促效劑市場分析工具
    • 產業分析：波特五力模型
    • PESTEL 分析
  • 定價分析
  • 管道分析
  • 專利到期分析

第4章 GLP-1受體促效劑市場：依產品分類的估算與趨勢分析

  • 全球GLP-1受體促效劑市場：產品概覽
  • 全球GLP-1受體促效劑市場：產品差異分析
  • 奧森皮克
  • 雷貝爾蘇斯
  • Trulicity
  • 薩克森達
  • 烏哥比
  • 維克托扎
  • 曼加羅
  • 齊柏林飛船
  • 其他

第5章 GLP-1受體促效劑市場：按應用分類的估算與趨勢分析

  • 全球GLP-1受體促效劑市場：應用概覽
  • 全球GLP-1受體促效劑市場：按應用領域分析變化
  • 2型糖尿病
  • 肥胖

第6章 GLP-1受體促效劑市場：依給藥途徑分類的估算與趨勢分析

  • 全球GLP-1受體促效劑市場依給藥途徑分類概覽
  • 全球GLP-1受體促效劑市場：按給藥途徑分類的差異分析
  • 腸外
  • 口服

第7章 GLP-1受體促效劑市場：依通路分類的估算與趨勢分析

  • 全球GLP-1受體促效劑市場：按分銷管道分類的概覽
  • 全球GLP-1受體促效劑市場：依通路分析市場波動
  • 醫院藥房
  • 零售藥房
  • 網路藥房

第8章：GLP-1受體促效劑市場：區域預測與趨勢分析

  • 區域儀錶板
  • 市場規模、預測與趨勢分析（2021-2033）：
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第9章 競爭情勢

  • 公司/競爭對手分類
  • 參與公司概況
  • Financial Overview
  • 產品基準測試
  • 2025年企業市場占有率分析
  • 策略規劃
  • 公司簡介
    • Eli Lilly and Company.
    • Sanofi
    • Novo Nordisk A/S
    • AstraZeneca.
Product Code: GVR-4-68038-694-3

GLP-1 Receptor Agonist Market Summary

The global GLP-1 receptor agonist market size was estimated at USD 70.08 billion in 2025 and is projected to reach USD 201.79 billion by 2033, growing at a CAGR of 12.78% from 2026 to 2033. The launch of new glucagon-like peptide 1 (GLP-1) receptor agonist products, a robust product pipeline for both diabetes & obesity applications, and the high efficacy of these drugs are anticipated to propel market growth.

In May 2024, Innovent Biologics announced that its type 2 diabetes candidate, mazdutide, outperformed Eli Lilly's Trulicity (dulaglutide) in a Phase III trial. The study established that mazdutide was superior in glycemic control and provided numerous cardiometabolic benefits, comprising weight loss & improvements in blood lipid levels, liver enzymes, serum uric acid, & blood pressure.

Other companies, such as Boehringer Ingelheim International GmbH, Carmot Therapeutics, Inc., D&D Pharmatech, Eli Lilly and Company (Lilly), and Hanmi Pharm. Co., Ltd, are also involved in developing new glucagon-like peptide 1 drugs. For instance, in October 2023, Carmot Therapeutics, Inc. published preliminary results from the single ascending dose (SAD) phase of an ongoing Phase 1 clinical trial for CT-996, an oral small molecule GLP-1 receptor agonist (RA) that is presently being assessed in a first-in-human clinical trial in individuals who are overweight or obese. Thus, increasing research in the field of GLP-1 receptor agonists is expected to drive market growth.

Moreover, the rising prevalence of obesity and diabetes is expected to drive the growth of the GLP-1 receptor agonist industry. The overweight and obese population is at a high risk of developing diabetes and cardiovascular illness. Worldwide obesity rates are rising, and it is widely acknowledged that this is one of the major public health issues of the present day. According to the World Heart Federation's global estimate, almost 2.3 billion children and adults worldwide suffer from obesity and overweight. Additionally, according to the Obesity Action Coalition (OAC), over 90% of individuals diagnosed with type 2 diabetes are either overweight or have some degree of obesity. Therefore, the rising obese and diabetes populations are driving the demand for GLP-1 receptor agonist drugs for treatment worldwide.

The high advantages associated with the use of GLP-1 drugs over other medicines, along with increasing investment in the R&D of new GLP-1 drugs, are driving market growth. Several GLP agonists have been linked to weight loss or weight neutrality, which is advantageous for people with diabetes since obesity frequently makes the disease worse. The lowering of appetite and the delayed stomach emptying contribute to the weight loss effect. Moreover, in November 2023, Novo Nordisk announced its intention to invest approximately 16 billion Danish kroner in developing GLP-1 drugs. This is roughly equivalent to USD 2.32 billion (€2.14 billion). These initiatives are anticipated to drive the market's growth.

Global GLP-1 Receptor Agonist Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global GLP-1 Receptor Agonist market report based on product, application, route of administration, distribution channel, and region:

  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Ozempic
  • Trulicity
  • Mounjaro
  • Wegovy
  • Rybelsus
  • Saxenda
  • Victoza
  • Zepbound
  • Other Products
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Type 2 Diabetes Mellitus
  • Obesity
  • Route of administration Outlook (Revenue, USD Million, 2021 - 2033)
  • Parenteral
  • Oral
  • Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • Kuwait
    • UAE

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Application
    • 1.2.3. Route of Administration
    • 1.2.4. Distribution Channel
    • 1.2.5. Regional scope
    • 1.2.6. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product and Application Outlook
    • 2.2.2. Route of Administration and Distribution Channel Outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. GLP-1 Receptor Agonist Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing prevalence of chronic diseases such as diabetes and obesity
      • 3.2.1.2. Increasing R&D activities for developing novel therapeutics
      • 3.2.1.3. Formulation advancements of oral GLP-1 receptor agonists
      • 3.2.1.4. Increasing awareness about diagnosis and treatment options for diabetes
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Product failure
      • 3.2.2.2. Patent expiry of blockbuster drugs during the forecast period
  • 3.3. GLP-1 Receptor Agonist Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
  • 3.4. Pricing Analysis
  • 3.5. Pipeline Analysis
  • 3.6. Patent Expiry Analysis

Chapter 4. GLP-1 Receptor Agonist Market: Product Estimates & Trend Analysis

  • 4.1. Global GLP-1 Receptor Agonist Market: Product Dashboard
  • 4.2. Global GLP-1 Receptor Agonist Market: Product Movement Analysis
  • 4.3. Ozempic
    • 4.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.4. Rybelsus
    • 4.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.5. Trulicity
    • 4.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.6. Saxenda
    • 4.6.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.7. Wegovy
    • 4.7.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.8. Victoza
    • 4.8.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.9. Mounjaro
    • 4.9.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.10. Zepbound
    • 4.10.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.11. Others
    • 4.11.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. GLP-1 Receptor Agonist Market: Application Estimates & Trend Analysis

  • 5.1. Global GLP-1 Receptor Agonist Market: Application Dashboard
  • 5.2. Global GLP-1 Receptor Agonist Market: Application Movement Analysis
  • 5.3. Type 2 Diabetes Mellitus
    • 5.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.4. Obesity
    • 5.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. GLP-1 Receptor Agonist Market: Route of Administration Estimates & Trend Analysis

  • 6.1. Global GLP-1 Receptor Agonist Market: Route of Administration Dashboard
  • 6.2. Global GLP-1 Receptor Agonist Market: Route of Administration Movement Analysis
  • 6.3. Parenteral
    • 6.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.4. Oral
    • 6.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. GLP-1 Receptor Agonist Market: Distribution Channel Estimates & Trend Analysis

  • 7.1. Global GLP-1 Receptor Agonist Market: Distribution Channel Dashboard
  • 7.2. Global GLP-1 Receptor Agonist Market: Distribution Channel Movement Analysis
  • 7.3. Hospital Pharmacies
    • 7.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4. Retail Pharmacies
    • 7.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5. Online Pharmacies
    • 7.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. GLP-1 Receptor Agonist Market: Regional Estimates & Trend Analysis By Product, Application, Route of Administration, and Distribution Channel

  • 8.1. Regional Dashboard
  • 8.2. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
  • 8.3. North America
    • 8.3.1. U.S.
      • 8.3.1.1. Key country dynamics
      • 8.3.1.2. Regulatory framework/ reimbursement structure
      • 8.3.1.3. Competitive scenario
      • 8.3.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.3.2. Canada
      • 8.3.2.1. Key country dynamics
      • 8.3.2.2. Regulatory framework/ reimbursement structure
      • 8.3.2.3. Competitive scenario
      • 8.3.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.3.3. Mexico
      • 8.3.3.1. Key country dynamics
      • 8.3.3.2. Regulatory framework/ reimbursement structure
      • 8.3.3.3. Competitive scenario
      • 8.3.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4. Europe
    • 8.4.1. UK
      • 8.4.1.1. Key country dynamics
      • 8.4.1.2. Regulatory framework/ reimbursement structure
      • 8.4.1.3. Competitive scenario
      • 8.4.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.4.2. Germany
      • 8.4.2.1. Key country dynamics
      • 8.4.2.2. Regulatory framework/ reimbursement structure
      • 8.4.2.3. Competitive scenario
      • 8.4.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.4.3. France
      • 8.4.3.1. Key country dynamics
      • 8.4.3.2. Regulatory framework/ reimbursement structure
      • 8.4.3.3. Competitive scenario
      • 8.4.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.4.4. Italy
      • 8.4.4.1. Key country dynamics
      • 8.4.4.2. Regulatory framework/ reimbursement structure
      • 8.4.4.3. Competitive scenario
      • 8.4.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.4.5. Spain
      • 8.4.5.1. Key country dynamics
      • 8.4.5.2. Regulatory framework/ reimbursement structure
      • 8.4.5.3. Competitive scenario
      • 8.4.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.4.6. Denmark
      • 8.4.6.1. Key country dynamics
      • 8.4.6.2. Regulatory framework/ reimbursement structure
      • 8.4.6.3. Competitive scenario
      • 8.4.6.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.4.7. Sweden
      • 8.4.7.1. Key country dynamics
      • 8.4.7.2. Regulatory framework/ reimbursement structure
      • 8.4.7.3. Competitive scenario
      • 8.4.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.4.8. Norway
      • 8.4.8.1. Key country dynamics
      • 8.4.8.2. Regulatory framework/ reimbursement structure
      • 8.4.8.3. Competitive scenario
      • 8.4.8.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5. Asia Pacific
    • 8.5.1. Japan
      • 8.5.1.1. Key country dynamics
      • 8.5.1.2. Regulatory framework/ reimbursement structure
      • 8.5.1.3. Competitive scenario
      • 8.5.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.5.2. China
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Regulatory framework/ reimbursement structure
      • 8.5.2.3. Competitive scenario
      • 8.5.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.5.3. India
      • 8.5.3.1. Key country dynamics
      • 8.5.3.2. Regulatory framework/ reimbursement structure
      • 8.5.3.3. Competitive scenario
      • 8.5.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.5.4. Australia
      • 8.5.4.1. Key country dynamics
      • 8.5.4.2. Regulatory framework/ reimbursement structure
      • 8.5.4.3. Competitive scenario
      • 8.5.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.5.5. South Korea
      • 8.5.5.1. Key country dynamics
      • 8.5.5.2. Regulatory framework/ reimbursement structure
      • 8.5.5.3. Competitive scenario
      • 8.5.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.5.6. Thailand
      • 8.5.6.1. Key country dynamics
      • 8.5.6.2. Regulatory framework/ reimbursement structure
      • 8.5.6.3. Competitive scenario
      • 8.5.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6. Latin America
    • 8.6.1. Brazil
      • 8.6.1.1. Key country dynamics
      • 8.6.1.2. Regulatory framework/ reimbursement structure
      • 8.6.1.3. Competitive scenario
      • 8.6.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.2. Argentina
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Regulatory framework/ reimbursement structure
      • 8.6.2.3. Competitive scenario
      • 8.6.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7. MEA
    • 8.7.1. South Africa
      • 8.7.1.1. Key country dynamics
      • 8.7.1.2. Regulatory framework/ reimbursement structure
      • 8.7.1.3. Competitive scenario
      • 8.7.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.7.2. Saudi Arabia
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Regulatory framework/ reimbursement structure
      • 8.7.2.3. Competitive scenario
      • 8.7.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.7.3. UAE
      • 8.7.3.1. Key country dynamics
      • 8.7.3.2. Regulatory framework/ reimbursement structure
      • 8.7.3.3. Competitive scenario
      • 8.7.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.7.4. Kuwait
      • 8.7.4.1. Key country dynamics
      • 8.7.4.2. Regulatory framework/ reimbursement structure
      • 8.7.4.3. Competitive scenario
      • 8.7.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Company/Competition Categorization
  • 9.2. Participant Overview
  • 9.3. Financial Overview
  • 9.4. Product Benchmarking
  • 9.5. Company Market Share Analysis, 2025
  • 9.6. Strategy Mapping
  • 9.7. Company Profiles
    • 9.7.1. Eli Lilly and Company.
      • 9.7.1.1. Company overview
      • 9.7.1.2. Financial performance
      • 9.7.1.3. benchmarking
      • 9.7.1.4. Strategic initiatives
    • 9.7.2. Sanofi
      • 9.7.2.1. Company overview
      • 9.7.2.2. Financial performance
      • 9.7.2.3. benchmarking
      • 9.7.2.4. Strategic initiatives
    • 9.7.3. Novo Nordisk A/S
      • 9.7.3.1. Company overview
      • 9.7.3.2. Financial performance
      • 9.7.3.3. benchmarking
      • 9.7.3.4. Strategic initiatives
    • 9.7.4. AstraZeneca.
      • 9.7.4.1. Company overview
      • 9.7.4.2. Financial performance
      • 9.7.4.3. benchmarking
      • 9.7.4.4. Strategic initiatives

List of Tables

  • Table 1 Index of Tables
  • Table 2 List of key distributors and channel partners
  • Table 3 List of key emerging companies/technology disruptors/innovators
  • Table 4 North America GLP-1 Receptor Agonist Market, by Country, 2021 - 2033 (USD Million)
  • Table 5 North America GLP-1 Receptor Agonist Market, by Product, 2021 - 2033 (USD Million)
  • Table 6 North America GLP-1 Receptor Agonist Market, by Application, 2021 - 2033 (USD Million)
  • Table 7 North America GLP-1 Receptor Agonist Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 8 North America GLP-1 Receptor Agonist Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 9 U.S. GLP-1 Receptor Agonist Market, by Product, 2021 - 2033 (USD Million)
  • Table 10 U.S. GLP-1 Receptor Agonist Market, by Application, 2021 - 2033 (USD Million)
  • Table 11 U.S.GLP-1 Receptor Agonist Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 12 U.S. GLP-1 Receptor Agonist Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 13 Canada GLP-1 Receptor Agonist Market, by Product, 2021 - 2033 (USD Million)
  • Table 14 Canada GLP-1 Receptor Agonist Market, by Application, 2021 - 2033 (USD Million)
  • Table 15 Canada GLP-1 Receptor Agonist Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 16 Canada GLP-1 Receptor Agonist Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 17 Mexico GLP-1 Receptor Agonist Market, by Product, 2021 - 2033 (USD Million)
  • Table 18 Mexico GLP-1 Receptor Agonist Market, by Application, 2021 - 2033 (USD Million)
  • Table 19 Mexico GLP-1 Receptor Agonist Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 20 Mexico GLP-1 Receptor Agonist Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 21 Europe GLP-1 Receptor Agonist Market, by Country, 2021 - 2033 (USD Million)
  • Table 22 Europe GLP-1 Receptor Agonist Market, by Product, 2021 - 2033 (USD Million)
  • Table 23 Europe GLP-1 Receptor Agonist Market, by Application, 2021 - 2033 (USD Million)
  • Table 24 Europe GLP-1 Receptor Agonist Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 25 Europe GLP-1 Receptor Agonist Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 26 Germany GLP-1 Receptor Agonist Market, by Product, 2021 - 2033 (USD Million)
  • Table 27 Germany GLP-1 Receptor Agonist Market, by Application, 2021 - 2033 (USD Million)
  • Table 28 Germany GLP-1 Receptor Agonist Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 29 Germany GLP-1 Receptor Agonist Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 30 UK GLP-1 Receptor Agonist Market, by Product, 2021 - 2033 (USD Million)
  • Table 31 UK GLP-1 Receptor Agonist Market, by Application, 2021 - 2033 (USD Million)
  • Table 32 UK GLP-1 Receptor Agonist Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 33 UK GLP-1 Receptor Agonist Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 34 France GLP-1 Receptor Agonist Market, by Product, 2021 - 2033 (USD Million)
  • Table 35 France GLP-1 Receptor Agonist Market, by Application, 2021 - 2033 (USD Million)
  • Table 36 France GLP-1 Receptor Agonist Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 37 France GLP-1 Receptor Agonist Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 38 Italy GLP-1 Receptor Agonist Market, by Product, 2021 - 2033 (USD Million)
  • Table 39 Italy GLP-1 Receptor Agonist Market, by Application, 2021 - 2033 (USD Million)
  • Table 40 Spain GLP-1 Receptor Agonist Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 41 Italy GLP-1 Receptor Agonist Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 42 Spain GLP-1 Receptor Agonist Market, by Product, 2021 - 2033 (USD Million)
  • Table 43 Spain GLP-1 Receptor Agonist Market, by Application, 2021 - 2033 (USD Million)
  • Table 44 Denmark GLP-1 Receptor Agonist Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 45 Spain GLP-1 Receptor Agonist Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 46 Denmark GLP-1 Receptor Agonist Market, by Product, 2021 - 2033 (USD Million)
  • Table 47 Denmark GLP-1 Receptor Agonist Market, by Application, 2021 - 2033 (USD Million)
  • Table 48 Denmark GLP-1 Receptor Agonist Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 49 Denmark GLP-1 Receptor Agonist Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 50 Sweden GLP-1 Receptor Agonist Market, by Product, 2021 - 2033 (USD Million)
  • Table 51 Sweden GLP-1 Receptor Agonist Market, by Application, 2021 - 2033 (USD Million)
  • Table 52 Sweden GLP-1 Receptor Agonist Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 53 Sweden GLP-1 Receptor Agonist Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 54 Norway GLP-1 Receptor Agonist Market, by Product, 2021 - 2033 (USD Million)
  • Table 55 Norway GLP-1 Receptor Agonist Market, by Application, 2021 - 2033 (USD Million)
  • Table 56 Norway GLP-1 Receptor Agonist Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 57 Norway GLP-1 Receptor Agonist Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 58 Asia Pacific GLP-1 Receptor Agonist Market, by Country, 2021 - 2033 (USD Million)
  • Table 59 Asia Pacific GLP-1 Receptor Agonist Market, by Product, 2021 - 2033 (USD Million)
  • Table 60 Asia Pacific GLP-1 Receptor Agonist Market, by Application, 2021 - 2033 (USD Million)
  • Table 61 Asia Pacific GLP-1 Receptor Agonist Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 62 Asia Pacific GLP-1 Receptor Agonist Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 63 Japan GLP-1 Receptor Agonist Market, by Product, 2021 - 2033 (USD Million)
  • Table 64 Japan GLP-1 Receptor Agonist Market, by Application, 2021 - 2033 (USD Million)
  • Table 65 Japan GLP-1 Receptor Agonist Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 66 Japan GLP-1 Receptor Agonist Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 67 China GLP-1 Receptor Agonist Market, by Product, 2021 - 2033 (USD Million)
  • Table 68 China GLP-1 Receptor Agonist Market, by Application, 2021 - 2033 (USD Million)
  • Table 69 China GLP-1 Receptor Agonist Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 70 China GLP-1 Receptor Agonist Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 71 India GLP-1 Receptor Agonist Market, by Product, 2021 - 2033 (USD Million)
  • Table 72 India GLP-1 Receptor Agonist Market, by Application, 2021 - 2033 (USD Million)
  • Table 73 India GLP-1 Receptor Agonist Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 74 India GLP-1 Receptor Agonist Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 75 Australia GLP-1 Receptor Agonist Market, by Product, 2021 - 2033 (USD Million)
  • Table 76 Australia GLP-1 Receptor Agonist Market, by Application, 2021 - 2033 (USD Million)
  • Table 77 Australia GLP-1 Receptor Agonist Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 78 Australia GLP-1 Receptor Agonist Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 79 South Korea GLP-1 Receptor Agonist Market, by Product, 2021 - 2033 (USD Million)
  • Table 80 South Korea GLP-1 Receptor Agonist Market, by Application, 2021 - 2033 (USD Million)
  • Table 81 South Korea GLP-1 Receptor Agonist Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 82 South Korea GLP-1 Receptor Agonist Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 83 Thailand GLP-1 Receptor Agonist Market, by Product, 2021 - 2033 (USD Million)
  • Table 84 Thailand GLP-1 Receptor Agonist Market, by Application, 2021 - 2033 (USD Million)
  • Table 85 Thailand GLP-1 Receptor Agonist Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 86 Thailand GLP-1 Receptor Agonist Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 87 Latin America GLP-1 Receptor Agonist Market, by Country, 2021 - 2033 (USD Million)
  • Table 88 Latin America GLP-1 Receptor Agonist Market, by Product, 2021 - 2033 (USD Million)
  • Table 89 Latin America GLP-1 Receptor Agonist Market, by Application, 2021 - 2033 (USD Million)
  • Table 90 Latin America GLP-1 Receptor Agonist Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 91 Latin America GLP-1 Receptor Agonist Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 92 Brazil GLP-1 Receptor Agonist Market, by Product, 2021 - 2033 (USD Million)
  • Table 93 Brazil GLP-1 Receptor Agonist Market, by Application, 2021 - 2033 (USD Million)
  • Table 94 Brazil GLP-1 Receptor Agonist Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 95 Brazil GLP-1 Receptor Agonist Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 96 Argentina GLP-1 Receptor Agonist Market, by Product, 2021 - 2033 (USD Million)
  • Table 97 Argentina GLP-1 Receptor Agonist Market, by Application, 2021 - 2033 (USD Million)
  • Table 98 Argentina GLP-1 Receptor Agonist Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 99 Argentina GLP-1 Receptor Agonist Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 100 MEA GLP-1 Receptor Agonist Market, by Country, 2021 - 2033 (USD Million)
  • Table 101 MEA GLP-1 Receptor Agonist Market, by Product, 2021 - 2033 (USD Million)
  • Table 102 MEA GLP-1 Receptor Agonist Market, by Application, 2021 - 2033 (USD Million)
  • Table 103 South Africa GLP-1 Receptor Agonist Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 104 MEA GLP-1 Receptor Agonist Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 105 South Africa GLP-1 Receptor Agonist Market, by Product, 2021 - 2033 (USD Million)
  • Table 106 South Africa GLP-1 Receptor Agonist Market, by Application, 2021 - 2033 (USD Million)
  • Table 107 South Africa GLP-1 Receptor Agonist Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 108 South Africa GLP-1 Receptor Agonist Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 109 Saudi Arabia GLP-1 Receptor Agonist Market, by Product, 2021 - 2033 (USD Million)
  • Table 110 Saudi Arabia GLP-1 Receptor Agonist Market, by Application, 2021 - 2033 (USD Million)
  • Table 111 Saudi Arabia GLP-1 Receptor Agonist Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 112 Saudi Arabia GLP-1 Receptor Agonist Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 113 UAE GLP-1 Receptor Agonist Market, by Product, 2021 - 2033 (USD Million)
  • Table 114 UAE GLP-1 Receptor Agonist Market, by Application, 2021 - 2033 (USD Million)
  • Table 115 UAE GLP-1 Receptor Agonist Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 116 UAE GLP-1 Receptor Agonist Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 117 Kuwait GLP-1 Receptor Agonist Market, by Product, 2021 - 2033 (USD Million)
  • Table 118 Kuwait GLP-1 Receptor Agonist Market, by Application, 2021 - 2033 (USD Million)
  • Table 119 Kuwait GLP-1 Receptor Agonist Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 120 Kuwait GLP-1 Receptor Agonist Market, by Distribution Channel, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 GLP-1 Receptor Agonist Market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain-based sizing & forecasting
  • Fig. 7 QFD modelling for market share assessment
  • Fig. 8 GLP-1 Receptor Agonist Market snapshot (2025)
  • Fig. 9 GLP-1 Receptor Agonist Market: Segment snapshot (2025)
  • Fig. 10 Competitive Insights (2025)
  • Fig. 11 Parent market outlook
  • Fig. 12 Related/ancillary market outlook
  • Fig. 13 GLP-1 Receptor Agonist Market driver impact
  • Fig. 14 GLP-1 Receptor Agonist Market restraint impact
  • Fig. 15 Porter's Five Forces Analysis
  • Fig. 16 SWOT Analysis, By Factor (Political & legal, Economic, and technological)
  • Fig. 17 Strategic alliance analysis
  • Fig. 18 Recent developments & impact analysis, by key market participants
  • Fig. 19 Key company market share analysis, 2025
  • Fig. 20 Company market position analysis
  • Fig. 21 Definition and scope, by product
  • Fig. 22 Product market share analysis, 2025 & 2033
  • Fig. 23 Segment dashboard
  • Fig. 24 Global GLP-1 Receptor Agonist Market, by product, 2021 - 2033 (USD Million)
  • Fig. 25 Ozempic market size & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 26 Rybelsus market size & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 27 Trulicity market size & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 28 Saxenda market size & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 29 Mounjaro market size & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 30 Victoza market size & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 31 Zepbound market size & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 32 Wegovy market size & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 33 Other market size & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 34 Definition and scope, by Application
  • Fig. 35 Application market share analysis, 2025 & 2033
  • Fig. 36 Segment dashboard.
  • Fig. 37 Global GLP-1 Receptor Agonist Market, by Application, 2021 - 2033 (USD Million)
  • Fig. 38 Type 2 diabetes mellitus market size & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 39 Obesity market size & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 40 Definition and scope by route of administration
  • Fig. 41 Route of administration market share analysis, 2025 & 2033
  • Fig. 42 Segment dashboard.
  • Fig. 43 Global GLP-1 Receptor Agonist Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Fig. 44 Parenteral market size & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 45 Oral market size & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 46 Definition and scope, by distribution channel
  • Fig. 47 Distribution channel market share analysis, 2025 & 2033
  • Fig. 48 Segment dashboard.
  • Fig. 49 Global GLP-1 Receptor Agonist Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Fig. 50 Hospital pharmacies market size & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 51 Retail pharmacies market size & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 52 Online pharmacies market size & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 53 North America market size, & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 54 U.S. market size, & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 55 Canada market size, & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 56 Mexico market size, & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 57 Europe market size, & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 58 UK market size, & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 59 Germany market size, & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 60 Spain market size, & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 61 France market size, & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 62 Italy market size, & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 63 Sweden market size, & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 64 Denmark market size, & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 65 Norway market size, & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 66 Asia Pacific market size, & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 67 China market size, & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 68 Japan market size, & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 69 India market size, & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 70 Australia market size, & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 71 South Korea market size, & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 72 Thailand market size, & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 73 Latin America market size, & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 74 Brazil market size, & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 75 Argentina market size, & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 76 Middle East and Africa market size, & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 77 South Africa market size, & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 78 Saudi Arabia market size, & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 79 UAE market size, & forecasts and trend analysis, 2021 to 2033(USD Million)
  • Fig. 80 Kuwait market size, & forecasts and trend analysis, 2021 to 2033(USD Million)